Company Encyclopedia
View More
name
Zoetis
ZTS.US
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health products in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics.
4.514 T
ZTS.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking42/184
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE49.87%A
    • Profit Margin28.21%A
    • Gross Margin71.58%A
  • Growth ScoreC
    • Revenue YoY2.68%C
    • Net Profit YoY9.09%C
    • Total Assets YoY5.59%B
    • Net Assets YoY3.13%C
  • Cash ScoreC
    • Cash Flow Margin354.47%C
    • OCF YoY2.68%C
  • Operating ScoreB
    • Turnover0.64B
  • Debt ScoreD
    • Gearing Ratio64.39%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Zoetis Inc. Stock Underperforms Thursday When Compared To Competitors

    Zoetis Inc. (ZTS) shares fell 1.76% to $120.41 on Thursday, marking the fourth consecutive day of losses. The stock underperformed compared to competitors like Merck & Co. Inc. and IDEXX Laboratories Inc. Trading volume was higher than the 50-day average. Zoetis is 33.79% below its 52-week high of $181.85. The S&P 500 rose 0.11%, while the Dow Jones fell 0.07%.

    Dow Jones·
    US
    ZTS
    -1.76%
    Dow Jones·
    US
    ZTS
    -1.76%

    Zoetis Inc. Stock Underperforms Wednesday When Compared To Competitors

    Zoetis Inc. (ZTS) shares fell 1.50% to $122.57 on Wednesday, underperforming compared to competitors like Merck & Co. Inc. (MRK), which rose 1.23%. This marks the third consecutive day of losses for Zoetis, with the stock 32.60% below its 52-week high. Trading volume was 4.9 million, above the 50-day average of 4.0 million.

    Dow Jones·
    US
    ZTS
    -1.76%
    Dow Jones·
    US
    ZTS
    -1.76%

    TD Cowen Reaffirms Their Buy Rating on Zoetis (ZTS)

    TD Cowen's Steve Scala reaffirmed a Buy rating on Zoetis with a $150 price target. Scala, a 5-star analyst, has a 10.7% average return and a 63.78% success rate. Zoetis also received a Buy rating from Bank of America Securities, while KeyBanc initiated coverage with a Hold rating.

    Tip Ranks·
    US
    ZTS
    -1.76%
    Tip Ranks·
    US
    ZTS
    -1.76%

    Zoetis Inc. Stock Underperforms Tuesday When Compared To Competitors

    Zoetis Inc. shares fell 2.21% to $124.44 on Tuesday, underperforming compared to competitors Merck & Co. and IDEXX Laboratories. This marked the second consecutive day of losses for Zoetis, which is 31.57% below its 52-week high. Trading volume was significantly higher than the 50-day average.

    Dow Jones·
    US
    ZTS
    -1.76%
    Dow Jones·
    US
    ZTS
    -1.76%

    Zoetis Inc. Files Initial Statement of Beneficial Ownership for Director Stephanie Tilenius

    Zoetis Inc. has filed a Form 3 with the SEC, naming Stephanie Tilenius as a beneficial owner in her role as Director. This filing is accessible via EDGAR, dated December 02, 2025.

    Reuters·
    US
    ZTS
    -1.76%
    Reuters·
    US
    ZTS
    -1.76%
    © 2025 Longbridge｜Disclaimer